In addition, we confirmed that PSB attenuated 5-FU chemoresistance in colon cancer by targeting LINC00612, which may provide a novel treatment strategy for 5-FU chemoresistance in colon cancer. This evidence concerns the gene LINC00612 and malignant colon neoplasm.